Drug Type Antibody-photosensitizer conjugates |
Synonyms ABY-029 trifluoroacetate salt |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Diagnostic dye |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Head and Neck Neoplasms | Phase 2 | United States | 24 Jan 2018 | |
Soft Tissue Sarcoma | Phase 2 | United States | 30 Aug 2017 | |
Recurrent Glioma | Phase 2 | United States | 13 Feb 2017 | |
Recurrent Glioma | Phase 2 | United States | 13 Feb 2017 | |
Glioma | Phase 1 | - | - | |
Glioma | Phase 1 | - | - | |
Glioma | Phase 1 | - | - |
Early Phase 1 | 14 | (ABY-029 1X Dose Group) | wilrmcpjms(snkqaydcyg) = ixyxmcfcel biwzqanlqk (aqhdfkvpwb, aayztzbqgt - exytcfyymk) View more | - | 13 Dec 2024 | ||
(ABY-029 3X Dose Group) | wilrmcpjms(snkqaydcyg) = jeqsbkolbm biwzqanlqk (aqhdfkvpwb, wlwsxjtkpj - aznvmskzkg) View more |